About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

DatScan With Prototype Collimator | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT02455219

DatScan With Prototype Collimator

A collimator is an accessory to a SPECT/CT scanner. It can be compared to a camera lens or filter that enhances or improves photos. The prototype collimators are able to magnify target organs about fo...

Lead sponsor: University of Minnesota•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Minnesota

Previously PET/CT has been used for this measurement but the L-DOPA is not FDA approved and thus of limited availability. DatScan (I123 ioflupane) is an FDA approved and clinically indicated biomarker, which has a high binding affinity for presynaptic dopamine transporters (DAT) in the brains of mammals, in particular the striatal region of the brain. A feature of Parkinson's disease is a marked reduction in dopaminergic neurons in the striatal region. By introducing an agent that binds to the dopamine transporters a quantitative measure and spatial distribution of the transporters can be obtained. The use of SPECT/CT (with the new validated collimators) and the FDA approved DATScan biomarker would allow for readily available diagnosis of Parkinson's disease

Age

50 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•all patients referred

Exclusion Criteria

•anyone who wishes to not participate and cannot lay on the table for an additional 30 minutes.

Related studies

Apathy in Parkinson Disease TMS Study

NCT06087926 · Parkinson Disease

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

NCT07642908 · Parkinson Disease

RECRUITINGPhase 2

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830 · Parkinson Disease, Parkinson, and more

Cognitive Decline Following Deep Brain Stimulation

NCT05822388 · Parkinson Disease, Movement Disorders

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

NCT06965374 · Parkinson Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 2, 2018Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment20

Start dateJun 2015

Last updatedMay 2, 2018

Condition

Parkinson Disease

Locations shown

University of Minnesota

Minneapolis, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 2, 2018Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions